Forbion — 2015 Investments

4 investments dated 2015 · listed companies and verified rows first · show all

Exosome Diagnostics inSeries A · Jun 2015 · $20M

BiotechHealthtechCambridge, US

James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)

BoardJoseph Boystak(Director)in

Board seatGeert-Jan Mulder· per SEC Form D

Co-investorsArcus Ventures NGN Capital

Inthera Bioscienceintherabio.comSeed · Dec 2015 · $4M

Inthera Bioscience AG is a biotech company with expertise spanning target discovery, drug discovery, medicinal chemistry, preclinical and toxicology work, and early clinical development.

BiotechDeep Tech

Mark Krul(Board of Directors)inKarl Rothweiler(Board of Directors)Martin Bonde(Board of Directors)

Co-investorsM Ventures

Prexton Therapeuticsprextontherapeutics.com inSeries A · Feb 2015 · $10Macquired by Lundbeck

Prexton Therapeutics was a biopharmaceutical company developing novel therapies for Parkinson's disease, including its lead mGluR4 modulator candidate foliglurax.

BiotechHealthtechMedical DevicesCopenhagen, DK

Co-investorsCardinal Partners M Ventures Seroba Life Sciences Sunstone Capital Ysios Capital

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Realeve

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.